Minireview: The case for obesogens

Molecular Endocrinology

Volumn 23, Issue 8, 2009, Pages 1127-1134

  Grün, Felix ^a   Blumberg, Bruce ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOGENESIS; CALORIC INTAKE; CARDIOVASCULAR DISEASE; ENERGY BALANCE; ENERGY EXPENDITURE; EPIDEMIC; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SHORT SURVEY; UNITED STATES; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; COMORBIDITY; DISEASE MODELS, ANIMAL; ENDOCRINE SYSTEM; ENERGY METABOLISM; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; MALE; MICE; OBESITY; STEROIDS;

EID: 67749101893     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2008-0485     Document Type: Short Survey

References (84)

1. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Näslund E, Britton T, Concha H, Hassan M, Rydén M, Frisén J, Arner P 2008 Dynamics of fat cell turnover in humans. Nature 453:783-787
2. Grün F, Blumberg B 2009 Endocrine disrupters as obesogens. Mol Cell Endocrinol 304:19-29
3. Grün F, Blumberg B 2007 Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev Endocr Metab Disord 8:161-171
4. Ferre P 2004 The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53(Suppl 1):S43-S50
5. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM 1999 PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617
6. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T 2000 The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212-216
7. Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR 1998 Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339:953-959
8. Nakano R, Kurosaki E, Yoshida S, Yokono M, Shimaya A, Maruyama T, Shibasaki M 2006 Antagonism of peroxisome proliferator-activated receptor γ prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol 72:42-52
9. Nishiu J, Ito M, Ishida Y, Kakutani M, Shibata T, Matsushita M, Shindo M 2006 JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor γ in vitro and in vivo. Diabetes Obes Metab 8:508-516
10. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W 2002 A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628 - 2644
11. Goldberg RB 2007 The new clinical trials with thiazolidinediones- DREAM, ADOPT, and CHICAGO: promises fulfilled? Curr Opin Lipidol 18:435-442
12. Larsen TM, Toubro S, Astrup A 2003 PPARγagonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 27:147-161
13. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B 2007 Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771:1065-1081
14. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H, Sairam MR 2000 Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology 141:4295-4308
15. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS 2000 Increased adipose tissue in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci USA 97:12729-12734
16. Matsumoto T, Takeyama K, Sato T, Kato S 2003 Androgen receptor functions from reverse genetic models. J Steroid Biochem Mol Biol 85:95-99
17. Murata Y, Robertson KM, Jones ME, Simpson ER 2002 Effect of estrogen deficiency in the male: the ArKO mouse model. Mol Cell Endocrinol 193: 7-12
18. Haarbo J, Marslew U, Gotfredsen A, Christiansen C 1991 Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 40:1323-1326
19. Kim HK, Nelson-Dooley C, Della-Fera MA, Yang JY, Zhang W, Duan J, Hartzell DL, Hamrick MW, Baile CA 2006 Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J Nutr 136:409-414
20. Wu J, Oka J, Tabata I, Higuchi M, Toda T, Fuku N, Ezaki J, Sugiyama F, Uchiyama S, Yamada K, Ishimi Y 2006 Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial. J Bone Miner Res 21:780-789
21. Ruhlen RL, Howdeshell KL, Mao J, Taylor JA, Bronson FH, Newbold RR, Welshons WV, vom Saal FS 2008 Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice. Environ Health Perspect 116:322-328
22. Penza M, Montani C, Romani A, Vignolini P, Pampaloni B, Tanini A, Brandi ML, Alonso-Magdalena P, Nadal A, Ottobrini L, Parolini O, Bignotti E, Calza S, Maggi A, Grigolato PG, Di Lorenzo D 2006 Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology 147:5740-5751
23. Newbold RR, Padilla-Banks E, Jefferson WN 2006 Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. Endocrinology 147(Suppl 6):S11-S17
24. Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN 2007 Perinatal exposure to environmental estrogens and the development of obesity. Mol Nutr Food Res 51:912-917
25. Newbold RR, Padilla-Banks E, Jefferson WN, Heindel JJ 2008 Effects of endocrine disruptors on obesity. Int J Androl 31:201-208
26. Baptista T, De Mendoza S, Beaulieu S, Bermú dez A, Martinez M 2004 The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Disord 2:290-307
27. Nemeroff CB 1997 Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 58(Suppl 10):45-49
28. Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN 2005 [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]. Encephale 31:507-516
29. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW 2002 Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 325:243
30. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC 2002 The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856-865
31. de Jesus LA, Carvalho SD, Ribeiro MO, Schneider M, Kim SW, Harney JW, Larsen PR, Bianco AC 2001 The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J Clin Invest 108:1379-1385
32. Festuccia WT, Oztezcan S, Laplante M, Berthiaume M, Michel C, Dohgu S, Denis RG, Brito MN, Brito NA, Miller DS, Banks WA, Bartness TJ, Richard D, Deshaies Y 2008 Peroxisome proliferator-activated receptor-γ-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 149:2121-2130
33. Achard V, Boullu-Ciocca S, Desbriére R, Grino M 2006 Perinatal programming of central obesity and the metabolic syndrome: role of glucocorticoids. Metab Syndr Relat Disord 4:129-137
34. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR 1998 Glucocorticoid exposure in late gestation permanently programs rat hepatic phos-phoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Invest 101:2174-2181
35. Pasquali R, Vicennati V, Cacciari M, Pagotto U 2006 The hypothalamicpituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann NY Acad Sci 1083:111-128
36. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS 2005 Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54:1023-1031
37. Odermatt A, Gumy C, Atanasov AG, Dzyakanchuk AA 2006 Disruption of glucocorticoid action by environmental chemicals: potential mechanisms and relevance. J Steroid Biochem Mol Biol 102:222-231
38. Tomlinson JW, Sherlock M, Hughes B, Hughes SV, Kilvington F, Bartlett W, Courtney R, Rejto P, Carley W, Stewart PM 2007 Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 92:857-864
39. Lindsay RS, Lindsay RM, Waddell BJ, Seckl JR 1996 Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 β-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 39: 1299-1305
40. Welberg LA, Seckl JR, Holmes MC 2000 Inhibition of 11β-hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring. Eur J Neurosci 12:1047-1054
41. Atanasov AG, Tam S, Rö cken JM, Baker ME, Odermatt A 2003 Inhibition of 11 β-hydroxysteroid dehydrogenase type 2 by dithiocarbamates. Biochem Biophys Res Commun 308:257-262
42. Inoue K, Kato K, Yoshimura Y, Makino T, Nakazawa H 2000 Determination of bisphenol A in human serum by high-performance liquid chromatography with multi-electrode electrochemical detection. J Chromatogr B Biomed Sci Appl 749:17-23
43. vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, Farabollini F, Guillette Jr LJ, Hauser R, Heindel JJ, Ho SM, Hunt PA, Iguchi T, Jobling S, Kanno J, Keri RA, Knudsen KE, Laufer H, LeBlanc GA, Marcus M, McLachlan JA, Myers JP, Nadal A, Newbold RR, Olea N, et al. 2007 Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod Toxicol 24:131-138
44. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y 2004 Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J 51:165-169
45. Masuno H, Iwanami J, Kidani T, Sakayama K, Honda K 2005 Bisphenol A accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. Toxicol Sci 84:319-327
46. Masuno H, Kidani T, Sekiya K, Sakayama K, Shiosaka T, Yamamoto H, Honda K 2002 Bisphenol A in combination with insulin can accelerate the conversion of 3T3-L1 fibroblasts to adipocytes. J Lipid Res 43:676-684
47. Masuno H, Okamoto S, Iwanami J, Honda K, Shiosaka T, Kidani T, Sakayama K, Yamamoto H 2003 Effect of 4-nonylphenol on cell proliferation and adipocyte formation in cultures of fully differentiated 3T3-L1 cells. Toxicol Sci 75:314-320
48. Sakurai K, Kawazuma M, Adachi T, Harigaya T, Saito Y, Hashimoto N, Mori C 2004 Bisphenol A affects glucose transport in mouse 3T3-F442A adipocytes. Br J Pharmacol 141:209-214
49. Phrakonkham P, Viengchareun S, Belloir C, Lombes M, Artur Y, Canivenc-Lavier MC 2008 Dietary xenoestrogens differentially impair 3T3-L1 preadipocyte differentiation and persistently affect leptin synthesis. J Steroid Biochem Mol Biol 110:95-103
50. Thomas P, Dong J 2006 Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 102:175-179
51. Miyawaki J, Sakayama K, Kato H, Yamamoto H, Masuno H 2007 Perinatal and postnatal exposure to bisphenol A increases adipose tissue mass and serum cholesterol level in mice. J Atheroscler Thromb 14:245-252
52. Rubin BS, Murray MK, Damassa DA, King JC, Soto AM 2001 Perinatal exposure to low doses of bisphenol A affects body weight, patterns of estrous cyclicity, and plasma LH levels. Environ Health Perspect 109:675-680
53. Grün F, Watanabe H, Zamanian Z, Maeda L, Arima K, Chubacha R, Gardiner DM, Kanno J, Iguchi T, Blumberg B 2006 Endocrine disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol 20:2141-2155
54. Kanayama T, Kobayashi N, Mamiya S, Nakanishi T, Nishikawa J 2005 Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor γ/retinoid X receptor pathway. Mol Pharmacol 67:766-774
55. Inadera H, Shimomura A 2005 Environmental chemical tributyltin augments adipocyte differentiation. Toxicol Lett 159:226-234
56. Carfi' M, Croera C, Ferrario D, Campi V, Bowe G, Pieters R, Gribaldo L 2008 TBTC induces adipocyte differentiation in human bone marrow long term culture. Toxicology 249:11-18
57. Janer G, Navarro JC, Porte C 2007 Exposure to TBT increases accumulation of lipids and alters fatty acid homeostasis in the ramshorn snail Marisa cornuarietis. Comp Biochem Physiol C Toxicol Pharmacol 146:368-374
58. Atanasov AG, Nashev LG, Tam S, Baker ME, Odermatt A 2005 Organotins disrupt the 11β-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids. Environ Health Perspect 113:1600-1606
59. Cooke GM, Forsyth DS, Bondy GS, Tachon R, Tague B, Coady L 2008 Organotin speciation and tissue distribution in rat dams, fetuses, and neonates following oral administration of tributyltin chloride. J Toxicol Environ Health A 71:384-395
60. Strand J, Jacobsen JA 2005 Accumulation and trophic transfer of organotins in a marine food web from the Danish coastal waters. Sci Total Environ 350:72-85
61. Takahashi S, Mukai H, Tanabe S, Sakayama K, Miyazaki T, Masuno H 1999 Butyltin residues in livers of humans and wild terrestrial mammals and in plastic products. Environ Pollut 106:213-218
62. Rantakokko P, Turunen A, Verkasalo PK, Kiviranta H, Männistö S, Vartiainen T 2008 Blood levels of organotin compounds and their relation to fish consumption in Finland. Sci Total Environ 399:90-95
63. Kannan K, Senthilkumar K, Giesy J 1999 Occurrence of butyltin compounds in human blood. Environ Sci Tech 33:1776-1779
64. Hurst CH, Waxman DJ 2003 Activation of PPARα and PPARβ by environmental phthalate monoesters. Toxicol Sci 74:297-308
65. Kaya T, Mohr SC, Waxman DJ, Vajda S 2006 Computational screening of phthalate monoesters for binding to PPARγ. Chem Res Toxicol 19:999-1009
66. Maloney EK, Waxman DJ 1999 trans-Activation of PPARα and PPARβ by structurally diverse environmental chemicals. Toxicol Appl Pharmacol 161: 209-218
67. Rosen MB, Lee JS, Ren H, Vallanat B, Liu J, Waalkes MP, Abbott BD, Lau C, Corton JC 2008 Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR α and CAR. Toxicol Sci 103:46-56
68. Shipley JM, Hurst CH, Tanaka SS, DeRoos FL, Butenhoff JL, Seacat AM, Waxman DJ 2004 trans-activation of PPARα and induction of PPARα target genes by perfluorooctane-based chemicals. Toxicol Sci 80:151-160
69. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ 2006 Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-α, -β, and -γ, liver X receptor-β, and retinoid X receptor-α. Toxicol Sci 92:476-489
70. Itsuki-Yoneda A, Kimoto M, Tsuji H, Hiemori M, Yamashita H 2007 Effect of a hypolipidemic drug, di (2-ethylhexyl) phthalate, on mRNA-expression associated fatty acid and acetate metabolism in rat tissues. Biosci Biotechnol Biochem 71:414-420
71. Xie Y, Yang Q, Nelson BD, DePierre JW 2002 Characterization of the adipose tissue atrophy induced by peroxisome proliferators in mice. Lipids 37:139-146
72. Wolf CJ, Fenton SE, Schmid JE, Calafat AM, Kuklenyik Z, Bryant XA, Thibodeaux J, Das KP, White SS, Lau CS, Abbott BD 2007 Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicol Sci 95:462-473
73. Betts KS 2007 Perfluoroalkyl acids: what is the evidence telling us ? Environ Health Perspect 115:A250-A256
74. Rosen MB, Abbott BD, Wolf DC, Corton JC, Wood CR, Schmid JE, Das KP, Zehr RD, Blair ET, Lau C 2008 Gene profiling in the livers of wild-type and PPARα-null mice exposed to perfluorooctanoic acid. Toxicol Pathol 36:592-607
75. Takacs ML, Abbott BD 2007 Activation of mouse and human peroxisome proliferator-activated receptors (α, β/δ, γ) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci 95:108-117
76. Tsumura Y, Ishimitsu S, Saito I, Sakai H, Tsuchida Y, Tonogai Y 2003 Estimated daily intake of plasticizers in 1-week duplicate diet samples following regulation of DEHP-containing PVC gloves in Japan. Food Addit Contam 20:317-324
77. Centers for Disease Control and Prevention 2005 Third national report on human exposure to environmental chemicals. Atlanta, GA: Center for Disease Control
78. Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH 2007 Concen-trations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect 115:876-882
79. Feige JN, Gelman L, Rossi D, Zoete V, Métivier R, Tudor C, Anghel SI, Grosdidier A, Lathion C, Engelborghs Y, Michielin O, Wahli W, Desvergne B 2007 The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor γ modulator that promotes adipogenesis. J Biol Chem 282:19152-19166
80. Smith SR, Lovejoy JC, Greenway F, Ryan D, deJonge L, de la Bretonne J, Volafova J, Bray GA 2001 Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 50:425-435
81. Tinsley FC, Taicher GZ, Heiman ML 2004 Evaluation of a quantitative magnetic resonance method for mouse whole body composition analysis. Obes Res 12:150-160
82. Carlin KM, Vale WW, Bale TL 2006 Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proc Natl Acad Sci USA 103:3462-3467
83. Paulik MA, Buckholz RG, Lancaster ME, Dallas WS, Hull-Ryde EA, Weiel JE, Lenhard JM 1998 Development of infrared imaging to measure thermogenesis in cell culture: thermogenic effects of uncoupling protein-2, troglitazone, and β-adrenoceptor agonists. Pharm Res 15:944-949
84. Tepper M, Persinger R, Daniels K, Chomicz S, Teich J 2003 Military infrared technology advances diabetes research. Diabetes Technol Ther 5:283-288